DOSAGE & ADMINISTRATION SECTION.
DOSAGE AND ADMINISTRATION:. Usual Dosage: Removal of foreign bodies and sutures, and for tonometry: to drops (in single instillations) in each eye before operating.Short Corneal and Conjunctival Procedures: drop in each eye every to 10 minutes for to doses.NOTE: ALCAINE(TM) (proparacaine hydrochloride ophthalmic solution, USP) 0.5% should be clear to straw-color. If the solution becomes darker, discard the solution.
Citing DrugCentral © 2026. License
GERIATRIC USE SECTION.
Geriatric Use:. No overall clinical differences in safety or effectiveness have been observed between the elderly and other adult patients.
Citing DrugCentral © 2026. License
HOW SUPPLIED SECTION.
HOW SUPPLIED:. ALCAINE(TM) (proparacaine hydrochloride ophthalmic solution, USP) 0.5% is supplied in DROP-TAINER(R) dispensers as follows:15 mL NDC 0998-0016-15Storage: Bottle must be stored in unit carton to protect contents from light. Store bottles under refrigeration at 2C to 8C (36F to 46F).After opening, ALCAINE(TM) can be used until the expiration date on the bottle.NOTE: ALCAINE(TM) (proparacaine hydrochloride ophthalmic solution, USP) 0.5% should be clear to straw-color. If the solution becomes darker, discard the solution.Distributed by:ALCON LABORATORIES, INC.Fort Worth, Texas 76134Revised: 06/2024 Alcon Alcon Laboratories, Inc. 6201 South Freeway Fort Worth, Texas 76134 USA (C) 2024 Alcon Inc. Printed in USAalcon.medinfoalcon.com 1-800-757-9195 300063110-0723.
Citing DrugCentral © 2026. License
CONTRAINDICATIONS SECTION.
CONTRAINDICATIONS:. ALCAINE(TM) ophthalmic solution should be considered contraindicated in patients with known hypersensitivity to any of the ingredients of this preparation.
Citing DrugCentral © 2026. License
INDICATIONS & USAGE SECTION.
INDICATIONS AND USAGE:. ALCAINE(TM) ophthalmic solution is indicated for procedures in which topical ophthalmic anesthetic is indicated: corneal anesthesia of short duration, e.g. tonometry, gonioscopy, removal of corneal foreign bodies, and for short corneal and conjunctival procedures.
Citing DrugCentral © 2026. License
DESCRIPTION SECTION.
DESCRIPTION:. ALCAINE(TM) (proparacaine hydrochloride ophthalmic solution, USP) 0.5% is topical local anesthetic for ophthalmic use. The active ingredient is represented by the structural formula:Established Name: Proparacaine Hydrochloride Chemical Name: Benzoic acid, 3-amino-4-propoxy-,2-(diethylamino) ethyl ester, monohydrochloride. Molecular Weight: 330.85 g/molEach mL contains of ALCAINE(TM) (proparacaine hydrochloride ophthalmic solution, USP) 0.5%: Active: proparacaine hydrochloride mg 0.5%. Preservative: benzalkonium chloride (0.01%). Inactives: glycerin and purified water. The pH may be adjusted with hydrochloric acid and/or sodium hydroxide.. chemical.
Citing DrugCentral © 2026. License
NURSING MOTHERS SECTION.
Nursing Mothers:. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when proparacaine hydrochloride is administered to nursing woman.
Citing DrugCentral © 2026. License
ADVERSE REACTIONS SECTION.
ADVERSE REACTIONS:. Occasional temporary stinging, burning and conjunctival redness may occur with the use of proparacaine. Corneal edema has been reported following the use of proparacaine. rare, severe, immediate-type, apparently hyperallergic corneal reaction characterized by acute, intense and diffuse epithelial keratitis, gray, ground glass appearance, sloughing of large areas of necrotic epithelium, corneal filaments and, sometimes, iritis with descemetitis has been reported.Allergic contact dermatitis from proparacaine with drying and fissuring of the fingertips has also been reported.
Citing DrugCentral © 2026. License
CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION.
Carcinogenesis, Mutagenesis, Impairment of Fertility.. Long-term studies in animals have not been performed to evaluate carcinogenic potential, mutagenicity, or possible impairment of fertility in males or females.
Citing DrugCentral © 2026. License
CLINICAL PHARMACOLOGY SECTION.
CLINICAL PHARMACOLOGY:. ALCAINE(TM) ophthalmic solution is rapidly-acting topical anesthetic, with induced anesthesia lasting approximately 10-20 minutes.
Citing DrugCentral © 2026. License
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL.
PRINCIPAL DISPLAY PANEL. NDC 0998-0016-15 Alcon Alcaine(TM) (proparacaine hydrochloride ophthalmic solution USP) 0.5% 15 mL Sterile Rx Only PRECAUTION: NOT FOR INJECTION. FOR TOPICAL OPHTHALMIC USE ONLY. Do not touch dropper tip to any surface, as this may contaminate the solution. USUAL DOSAGE: or drops. Read enclosed insert. Bottles must be stored in unit carton to protect from light. STORAGE: Store between 2o to 8oC (36o to 46oF). After opening, ALCAINE(TM) can be used until the expiration date on the bottle. ALCAINE(TM) (proparacaine hydrochloride ophthalmic solution) should be clear to straw-color. If the solution becomes darker, discard the solution. INGREDIENTS: Each mL contains: Active: proparacaine hydrochloride mg (0.5%). Preservative: benzalkonium chloride 0.01%. Inactives: glycerin, hydrochloric acid and/or sodium hydroxide (to adjust pH), purified water pH range 4.0 to 6.0 1-800-757-9195alcon.medinfoalcon.comCountry of Origin: Switzerland Alcon ALCON LABORATORIES, INC. 6201 South FreewayFort Worth, Texas 76134 USA Printed in USA 300056033-0922 NDC 0998-0016-15 Alcon Alcaine(TM) (proparacaine hydrochloride ophthalmic solution USP) 0.5% Sterile 15 mL Rx Only PRECAUTION: NOT FOR INJECTION. FOR TOPICAL OPHTHALMIC USE ONLY. Do not touch dropper tip to any surface as this may contaminate the solution. USUAL DOSAGE: or drops. Read enclosed insert. STORAGE: Store between 2o to 8oC (36o to 46oF).After opening, ALCAINE(TM) can be used until the expiration date on the bottle. Bottles must be stored in unit carton to protect from light. ALCAINE(TM) (proparacaine hydrochloride ophthalmic solution) should be clear to straw-color. If the solution becomes darker, discard the solution. INGREDIENTS: Each mL contains: Active: proparacaine hydrochloride mg (0.5%). ALCON LABORATORIES, INC. Fort Worth, Texas 76134 USA Printed in USA LOT/EXP.:.
Citing DrugCentral © 2026. License
PEDIATRIC USE SECTION.
Pediatric Use:. Safety and effectiveness of proparacaine hydrochloride ophthalmic solution in pediatric patients have been established. Use of proparacaine hydrochloride is supported by evidence from adequate and well-controlled studies in adults and children over the age of twelve, and safety information in neonates and other pediatric patients.
Citing DrugCentral © 2026. License
PRECAUTIONS SECTION.
PRECAUTIONS:. Carcinogenesis, Mutagenesis, Impairment of Fertility.. Long-term studies in animals have not been performed to evaluate carcinogenic potential, mutagenicity, or possible impairment of fertility in males or females.. Pregnancy:. Animal reproduction studies have not been conducted with ALCAINE(TM) (proparacaine hydrochloride ophthalmic solution, USP) 0.5%. It is also not known whether proparacaine hydrochloride can cause fetal harm when administered to pregnant woman or can affect reproduction capacity. Proparacaine hydrochloride should be administered to pregnant woman only if clearly needed.
Citing DrugCentral © 2026. License
PREGNANCY SECTION.
Pregnancy:. Animal reproduction studies have not been conducted with ALCAINE(TM) (proparacaine hydrochloride ophthalmic solution, USP) 0.5%. It is also not known whether proparacaine hydrochloride can cause fetal harm when administered to pregnant woman or can affect reproduction capacity. Proparacaine hydrochloride should be administered to pregnant woman only if clearly needed.
Citing DrugCentral © 2026. License
WARNINGS SECTION.
WARNINGS:. NOT FOR INJECTION FOR TOPICAL OPHTHALMIC USE ONLY. Prolonged use of topical ocular anesthetic is not recommended. It may produce permanent corneal opacification with accompanying visual loss.ALCAINE(TM) ophthalmic solution is indicated for administration under the direct supervision of healthcare provider. ALCAINE(TM) ophthalmic solution is not intended for patient self-administration.
Citing DrugCentral © 2026. License